Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 10/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SPHK2 | Q9NRA0 | 7/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2965171 | 0.84 | SKP2 (0.37) | CA2SMN1; SMN2SKP2SPHK1CA1 | |
| SCHEMBL2965223 | 0.81 | SKP2 (0.36) | CA2SMN1; SMN2SKP2SPHK1CA1 | |
| SCHEMBL2972931 | 0.79 | CA2 (0.34) | CA2SMN1; SMN2SKP2SPHK1CA1 | |
| SCHEMBL2966539 | 0.79 | SKP2 (0.37) | CA2SMN1; SMN2SKP2SPHK1CA1 | |
| SCHEMBL2961494 | 0.79 | SKP2 (0.37) | CA2SMN1; SMN2SKP2SPHK1CA1 | |
| SCHEMBL2961855 | 0.78 | SKP2 (0.39) | CA2SMN1; SMN2SKP2SPHK1CA1 | |
| SCHEMBL2964482 | 0.78 | CYSLTR2 (0.34) | — | |
| SCHEMBL2969463 | 0.77 | GID4 (0.30) | — | |
| SCHEMBL16390571 | 0.71 | HTR6 (0.38) | CA2SPHK1CA1ALDH1A1HPGD | |
| SCHEMBL2964433 | 0.70 | SKP2 (0.36) | CA2SMN1; SMN2SKP2SPHK1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763562-B2 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
| WO-2006065809-A2 | HETEROATOM BRIDGED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | AP2M1, AP1M1, PYM1 | CA2 3440/4885SMN1; SMN2 4156/4885SKP2 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.